– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application...
The NDA submission is being reviewed under the FDA's Real-Time Oncology Review (RTOR) programme and includes data from the phase...
SpringWorks Therapeutics, Inc.STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused...
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. SpringWorks Therapeutics,...
Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key...
– Activities to Enable the Topline Analysis from Phase 3 DeFi Trial Underway with Data Expected in the Second Quarter...